AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04923646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primer
Description: Mailed postcard notifying Veteran of upcoming FIT kit for annual CRC screening.
Study NCT06055465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: * 4 cycles, each cycle lasting for 3 weeks~* 10mg/kg given every day 1 and day 8 each cycle~* IV infusion
Study NCT06055465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: * 4 cycles, each cycle lasting for 3 weeks in Neoadjuvant phase; after surgery, 13 cycles, each cycle lasting for 3 weeks in Maintenance phase.~* 200mg fixed dose every day 1 each cycle~* IV infusion
Study NCT06066905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chidamide and azacitidine
Description: chidamide：10mg orally,day 1 to day 6 every week, Take it for two weeks, rest for two weeks,so 28 days for a circle, 12 circles totally.~azacitidine:50mg,subcutaneous injection,day 1 to day 5 every week, 28 days for a circle, 6 circles totally.
Study NCT04153838 — intervention group
Intervention type: OTHER
Intervention: Cognitive test administration
Description: Specifically chosen cognitive tests will be administered to all participants twice; with an approximate 12 month gap between initial testing and follow-up testing.
Study NCT06524570 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIFU-HT
Description: High-Intensify Focused Ultrasound Histotripsy
Study NCT06524570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICI
Description: Ipilimumab and nivolumab
Study NCT06306664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioptron
Description: Bioptron safely treats arthritis, neck \& back pain by stimulating blood circulation, reducing inflammation and relieving muscle spasms. For just ten minutes per day, our life-transforming technology offers the highest levels of pain relief by reaching deep into joints, muscles and ligaments.
Study NCT05404919 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hepatitis B Immune Globulin and entecavir, tenofovir disoproxil, or tenofovir alafenamide
Description: Anti-hepatitis B medications
Study NCT06306664 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Patients will receive ice application+Exercises program designed for jumper knee
Study NCT05685732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
Description: Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
Study NCT05685732 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo
Study NCT05149040 — intervention group
Intervention type: OTHER
Intervention: survey Intensive care of very elderly: What do they wish for themselves?
Description: self-administered mailed survey
Study NCT04831203 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: An egg-protein hydrolysate (NWT-03)
Description: As described in the experimental arm
Study NCT04831203 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: As described in the Control arm
Study NCT05893407 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measuring contrast-enhanced ultrasound perfusion with phase inversion harmonic imaging
Description: Contrast-enhanced ultrasound perfusion imaging (PerCEUS) will be performed by a dedicated study team. The transcranial color duplex sonography will be performed with a 1-5 MHz dynamic sector array (S5-1) from a Philips Epiq 7 ultrasound machine (Philips Healthcare, Andover, MA). The field-of-view will be set to an imaging depth of 150 mm in a sector angle of 90°. The imaging plane will be then tilted to the diencephalic, in which the frontal horns of the side ventricles and the third ventricle serve as landmarks and where the anterior and posterior middle cerebral artery (MCA) territory and the basal ganglia (BG) as region of interest could be identified without artefacts from major vessels. High mechanical index bolus imaging will be performed from the sanest side of the head. Data acquisition of 45 seconds will be recorded immediately after the beginning of the contrast ultrasound imaging, using a mechanical index (MI) setting of 1.1 and a frame rate of 33 Hz.
Study NCT04709406 — intervention group
Intervention type: DRUG
Intervention: deep neuromuscular blockade in bariatric surgery
Description: obese patients who underwent bariatric surgery
Study NCT06359886 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: B-Lynch Transverse Compression Suture
Description: closure of uterine and utero ovarian arteries bilaterally with one suture
Study NCT05068063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Injection
Description: Ultrasound-guided Femoral Triangle block with 20 mL of Bupivacaine 0.25% and IPACK block with 20 mL of Bupivacaine 0.25%
Study NCT03800017 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Hyperoxia
Description: Participants breathe 60% oxygen during exercise
Study NCT03800017 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hyperoxia
Description: Participants breathe 60% oxygen during exercise
Study NCT06218056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol (CBD) 800 mg
Description: CBD (400 mg) will be administered orally twice daily in the morning and again in the evening in 4 capsules each containing 100 mg of the active ingredient in the Ananda investigational new drug, ATL5. ATL5 is cannabidiol (CBD), extracted from hemp, at a 10% strength (softgel capsules with 100 mg/ml of CBD per capsule). The novel formulation is based on the principle that a water-free mixture of some concentrated inactive ingredients (excipients) self-assemble spontaneously into liquid nanodomains that contain the active component CBD. ATL5 Softgel Capsules will be manufactured by Baxco Pharmaceutical Inc., (California, USA) under cGMP conditions.
Study NCT06218056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo softgel capsule formulation will have a composition with the same relative proportions as the CBD ATL5 Softgel Capsules. This formulation will be manufactured by Baxco Pharmaceutical Inc under cGMP conditions. 4 softgel capsules of placebo will be administered to match the capsule number of the active compound, daily in the morning and evening for each of 56 days.
Study NCT05775523 — intervention group
Intervention type: DRUG
Intervention: No intervention
Description: No intervention
Study NCT04900701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy status
Description: Varying conditions of energy intake, thereby manipulating whether participants are in a state of energy restriction, balance, or surplus.
Study NCT05454670 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two-flap palatoplasty
Description: Two-flap palatoplasty used to correct cleft palate defect. The cleft palate is closed by separation of the nasal and the oral mucosa layers. Then approximation of the nasal mucosa layer, muscle layer is secured in the posterior palate and then the oral mucosa layer is secured
Study NCT05454670 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two-flap palatoplasty
Description: Two-flap palatoplasty used to correct cleft palate defect. The cleft palate is closed by separation of the nasal and the oral mucosa layers. Then approximation of the nasal mucosa layer, muscle layer is secured in the posterior palate and then the oral mucosa layer is secured
Study NCT05124769 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Allowing Program (PAllow)
Description: Performing exercises considered to have a considerable supraspinatus/ infraspinatus tendon/muscle load (EMG muscle activity of > 40% MVC).
Study NCT05124769 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Avoiding Program (PAvoid)
Description: Performing exercises selected to have a minimal insupraspinatus/ infraspinatus tendon/muscle load (EMG muscle activity of \<20% MVC).~These unloading exercises are performed for 6 weeks. In the second part of the exercise protocol, the loading exercises are applied, however without pain.~In case the patient still feels pain during the exercises in that period, the unloading exercises are continued.
Study NCT05456503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FPI-2620
Description: Radiotracer
Study NCT05856266 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US)
Description: Ultrasound examination
Study NCT05856266 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Haemophilia Joint Health Score (HJHS)
Description: Functional joint examination
Study NCT05858125 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Media Navigation Aid Kit
Description: The Social media Navigation Aid Kit (SNAK) was created by using search terms, urinary incontinence, urinary leakage, and urogynecology, and querying various websites/blogs, Facebook, Instagram, and YouTube. These social media platforms were chosen based on the top three social media platforms used in Americans aged 50 to >65 years old according to Pew Research Analytics (Pew paper). The experienced reviewer evaluated each platform for users that provided relevant, accurate, and specific content. The department of Urogynecology at UNM independently reviewed the curated pages and users for approval. Once approved, the various users and pages were then collected and a flyer was created. The flyer will be available via hardcopy, email, or text per patient preference.
Study NCT05778903 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nerve block
Description: Suprazygomatic maxillary nerve block
Study NCT06223087 — intervention group
Intervention type: OTHER
Intervention: winter swimming
Description: Intervention involves bathing/swimming in cold water during the winter months in open waters
Study NCT04484259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy
Description: Eligible patients will enter a 7-10 day run-in phase with aspirin 81 mg/ qd plus ticagrelor 90 mg bid after which they will discontinue aspirin and maintain ticagrelor 90 mg bid monotherapy for 10±3 days. After this period, patients will be randomized using a randomly generated computer sequence in a 1:1:1 fashion to either: a) ticagrelor 60 mg bid monotherapy; b) aspirin 81 mg qd plus ticagrelor 60 mg bid; c) aspirin 81 mg qd plus clopidogrel 75 mg qd. Randomized treatment will be maintained for 10±3 days.
Study NCT04484259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor plus aspirin
Description: Eligible patients will enter a 7-10 day run-in phase with aspirin 81 mg/ qd plus ticagrelor 90 mg bid after which they will discontinue aspirin and maintain ticagrelor 90 mg bid monotherapy for 10±3 days. After this period, patients will be randomized using a randomly generated computer sequence in a 1:1:1 fashion to either: a) ticagrelor 60 mg bid monotherapy; b) aspirin 81 mg qd plus ticagrelor 60 mg bid; c) aspirin 81 mg qd plus clopidogrel 75 mg qd. Randomized treatment will be maintained for 10±3 days.
Study NCT04484259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel with aspirin
Description: Eligible patients will enter a 7-10 day run-in phase with aspirin 81 mg/ qd plus ticagrelor 90 mg bid after which they will discontinue aspirin and maintain ticagrelor 90 mg bid monotherapy for 10±3 days. After this period, patients will be randomized using a randomly generated computer sequence in a 1:1:1 fashion to either: a) ticagrelor 60 mg bid monotherapy; b) aspirin 81 mg qd plus ticagrelor 60 mg bid; c) aspirin 81 mg qd plus clopidogrel 75 mg qd. Randomized treatment will be maintained for 10±3 days.
Study NCT05092373 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT05092373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO
Study NCT05092373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV
Study NCT05092373 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields Therapy
Description: Receive TTF
Study NCT06585033 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Spinal cord stimulation
Description: Stimulation off
Study NCT06585033 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal cord stimulation
Description: Stimulation on
Study NCT04939194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fast Track Protocol
Description: We will apply 22 items of ERAS society
Study NCT04234659 — intervention group
Intervention type: DEVICE
Intervention: Clinical placement of a temporary IMPELLA® mechanical circulatory support device.
Description: Surgical placement of the IMPELLA® device for life threatening cardiogenic shock not responsive to other medical treatment.
Study NCT06252220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DA-1726
Description: Active
Study NCT06252220 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DA-1726
Description: Active
Study NCT06252220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to DA-1726
Description: Placebo
Study NCT06252220 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to DA-1726
Description: Placebo
Study NCT04314895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension
Description: NanoPac is manufactured using a Precipitation with Compressed Antisolvent (PCA) technique that employs supercritical carbon dioxide and acetone to generate paclitaxel nanoparticles within a well-characterized particle-size distribution. Following PCA, NanoPac is filled into a clear 60mL Type 1, USP, clear-glass vial (306 mg/vial) as a powder fill of nanoparticulate paclitaxel, closed with a bromobutyl rubber stopper and aluminum crimp seal, and sterilized by gamma irradiation. Prior to administration at the hospital/clinic, NanoPac will be reconstituted with 1% Polysorbate 80, NF in 0.9% Sodium Chloride for Injection, USP, to form a suspension. The suspension will be further diluted with 0.9% Sodium Chloride for Injection, USP to achieve the final clinical formulation.
Study NCT05068063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal Saline
Description: Ultrasound-guided Femoral Triangle block with 20 mL of Bupivacaine 0.25% and IPACK block with 20 mL of normal saline 0.9%
Study NCT05734521 — intervention group
Intervention type: BIOLOGICAL
Intervention: avalglucosidase alfa-NGPT (GZ402666) IV
Description: intravenous infusion
Study NCT05734521 — intervention group
Intervention type: BIOLOGICAL
Intervention: avalglucosidase alfa-NGPT (GZ402666)
Description: exposed via pregnancy and lactation
Study NCT04560179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin solution for inhalation 78mg dose
Description: Inhaled tobramycin - 78mg administered every 12 hours for 14 days.
Study NCT04560179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin solution for inhalation 150mg dose
Description: Inhaled tobramycin - 150mg administered every 12 hours for 14 days.
Study NCT04560179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin solution for inhalation 216mg dose
Description: Inhaled tobramycin - 216mg administered every 12 hours for 14 days.
Study NCT04560179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin solution for inhalation 300mg dose
Description: Inhaled tobramycin - 300mg administered every 12 hours for 14 days.
Study NCT05169632 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Computerized Gaming Rehabilitation Program 1
Description: Brain training games with physical exercise component.
Study NCT05169632 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computerized Gaming Rehabilitation Program 2
Description: Cognitive training games with physical exercise component.
Study NCT06501716 — intervention group
Intervention type: PROCEDURE
Intervention: Indocyanine Green
Description: Tumor resection, direct visualization of the chiasm and both optic nerves and ICG administration will be provided as it is recommended by the standard of care. ICG will be administered by an injection of 5 mg of ICG diluted in a 10 mL syringe performed in the line closest to the heart followed by a 10-mL saline bolus. Using near-infrared lighting, the investigators will determine the time between anterior cerebral arteries (ACA) peak luminescence to the peak luminescence of the superior hypophyseal arteries enveloping the optic chiasm (ACA to chiasm time). Because luminescence of large vessels precedes small arterial penetration, signal from the ACAs was considered as time 0 to account for possible differences in the arm-brain time between patients. In addition, the investigators will analyze the proportion of superior hypophyseal branches on the chiasm that luminesced from ICG.
Study NCT05354739 — intervention group
Intervention type: DEVICE
Intervention: The vibration cold device (BUZZY)
Description: If the patient fulfils the inclusions criteria, the research nurse will obtain informed consent from a parent or legal guardian and assent form if the child is 7years or older. She will assess the ability of the child to use the Faces Pain Scale-Revised (FPS-R), as a pain assessment instrument used by the child. It is a six cartoon faces showing a normal facial expression if no pain, progressing into the facial expression with very severe pain. FPS-R is graded from zero to ten; the child will be asked to quantify the pain by: no hurt, hurt, or very much hurt. This scale is widely used not only in research but also in a routine bases in ours and other units by the nursing staff and are familiar with it. The research nurse is one of the nurses used the same scale during the routine work and will be trained further to ensure consistency, she will document the findings prior, during and after the procedure. This instrument was reliable, valid, and standardized
Study NCT05416788 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical manipulation
Description: high-velocity, low-amplitude cervical manipulation
Study NCT05416788 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham intervention
Description: lateral flexion and cervical rotation without manipulation
Study NCT06172335 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cetoleic acid
Description: Very long monounsaturated fatty acid (C22:1n-11)
Study NCT06172335 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control oil
Description: Mix of oils with low cetoleic acid content
Study NCT05995886 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wiidookaage'win Facebook Group
Description: An online social media group program that incorporates social support, mindfulness-based, and cultural practices that may support OUD recovery.
Study NCT04931849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Description: Avatrombopag is a small molecule thrombopoeitic receptor agonist (TPO-RA) that mimics the biological effects of thrombopoeitin (TPO)
Study NCT06091540 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feasibility and Efficacy of Individual SH+ Intervention
Description: The key parameter of interest will be the extent of psychological distress encountered by the participants. In addition, various secondary outcomes will also be evaluated, encompassing depression, anxiety, post-traumatic stress disorder (PTSD) symptoms, psychosocial well-being, and grief levels. The evaluation of the intervention's effectiveness on the sample of interest will hinge on the comparison of scores obtained during the pretest and posttest measurement phases.
Study NCT05128760 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: characterization of aPL
Description: characterization of aPL profile, GT profile and leukocytes activations markers (NETs, TREM-1)
Study NCT05437315 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bi-4SCAR GD2/PSMA T cells
Description: Infusion of bi-4SCAR GD2/PSMA T cells at 10\^6 cells/kg body weight via IV
Study NCT06574438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AIFIGA program
Description: receives the Artificial Intelligence Family Involvement Generative Agent (AIFIGA) program and uses it for 3 months
Study NCT04778085 — intervention group
Intervention type: BEHAVIORAL
Intervention: Illness management and recovery
Description: Treatment given in groups, weekly for 10-12 months.
Study NCT04778085 — intervention group
Intervention type: OTHER
Intervention: Semi-structured interviews
Description: Semi-structured individual or group interviews conducted three times with staff on each participating outpatient clinic.
Study NCT05440201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amount of anticoagulant Clexane
Description: Change (increase/decrease) the amount of Clexane administered at the dialysis start.
Study NCT05416320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriol
Description: Subjects will use the topical formulation once daily on the scalp. The subjects will use the treatment for a total of 6 months.
Study NCT05416320 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Subject's already prescribed drug
Description: Subjects will continue to use their already prescribed topical formulation once daily on the scalp. The subjects will use their treatment for a total of 6 months.
Study NCT05439083 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 9-valent HPV vaccine
Description: All participants will receive the immunization schedule according to guidelines: immunosuppressed patients will receive a three-dose schedule: 0.5 mL intramuscular injection of 9vHPV at entry plus an additional dose at month 2 and month 6. Healthy controls aged 9-14 years will receive a two-dose schedule: 0 and 6 months.